The DOI matches its Crossref record.
Endocrine Therapy of Breast Cancer
Abstract
Breast cancer remains one of the first leading causes of death in women, and currently endocrine treatment is of major therapeutic value in patients with estrogen-receptor positive tumors. Selective estrogen-receptor modulators (SERMs), such as tamoxifen and raloxifene, aromatase inhibitors, and GnRH agonists are the drugs of choice. Tamoxifen, a partial nonsteroidal estrogen agonist, is a type II competitive inhibitor of estradiol at its receptor, and the prototype of SERMs. Aromatase inhibitors significantly lower serum estradiol concentration in postmenopausal patients, having no detectable effects on adrenocortical steroids formation, while GnRH agonists suppress ovarian function, inducing a menopause- like condition in premenopausal women. Endocrine therapy has generally a relatively low morbidity, leading to a significant reduction of mortality for breast cancer. The aim of chemoprevention is to interfere early with the process of carcinogenesis, reducing the risk of cancer development. As preventive agents, raloxifene and tamoxifene are equivalent, while raloxifene has more potent antiresorptive effects in postmenopausal osteoporosis. Endocrine treatment is usually considered a standard choice for patients with estrogen-receptor positive cancers and non-life-threatening advanced disease, or for older patients unfit for aggressive chemotherapy regimens. Several therapeutic protocols used in patients with breast cancer are associated with bone loss, which may lead to an increased risk of fracture. Bisphosphonates are the drugs of choice to treat such a drug-induced bone disease. The aim of this review is to outline current understanding on endocrine therapy of breast cancer. Keywords: Breast cancer, endocrine therapy, chemoprevention, adjuvant therapy, SERM, tamoxifen, raloxifene, aromatase inhibitors, estrogen-receptor positive tumors, Selective estrogen-receptor modulators, GnRH agonists, serum estradiol, postmenopausal osteoporosis., Bisphosphonates, lymph node, ovarian suppres-sive drugs, estradiol, carcinogenesis, atypical hyperplasia, ovariectomy, adrenalec-tomy, hypophysectomy, Non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase (COX), Early Breast Cancer Trial-ists' Collaborative Group (EBCTCG), progesterone-receptor, gonadotropin-releasing hormone (GnRH), dual-energy x-ray absorptiometry (DXA), clodronate, risedronate, ibandronate, Osteonecrosis, prophylaxis
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Łukasiewicz, S., Czeczelewski, M., Forma, A., Baj, J., Sitarz, R., & Stanisławek, A. (2021) · Cancers · doi:10.3390/cancers13174287 · Cited by 1,960
European guidelines for quality assurance in breast cancer screening and diagnosis
Amendoeira, I., Perry, N., Broeders, M. J. M., de Wolf, C., Törnberg, S., Holland, R. D., & von Karsa, L. (2013) · Zurich Open Repository and Archive (University of Zurich) · doi:10.2772/13196 · Cited by 1,556
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
ABC Transporters in Multidrug Resistance and Pharmacokinetics, and Strategies for Drug Development
Choi, Y., & Yu, A.-M. (2014) · Current Pharmaceutical Design · doi:10.2174/138161282005140214165212 · Cited by 629
Paclitaxel’s Mechanistic and Clinical Effects on Breast Cancer
Abu Samaan, T. M., Samec, M., Liskova, A., Kubatka, P., & Büsselberg, D. (2019) · Biomolecules · doi:10.3390/biom9120789 · Cited by 569
Metadata
- Authors
- Lumachi, F., Luisetto, G., M.M. Basso, S., Basso, U., Brunello, A., & Camozzi, V.
- Venue
- Current Medicinal Chemistry
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2011-02-01
- Volume
- 18
- Issue
- 4
- Pages
- 513-522
- ISSN
- 0929-8673 (ISSN-L)
- OpenAlex
- W2109315042
- Cited by
- 176
- References
- 0
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Endocrine Therapy of Breast Cancer. https://app.cochat.ai/papers/10.2174/092986711794480177
- The paper
- Lumachi, F., Luisetto, G., M.M. Basso, S., Basso, U., Brunello, A., & Camozzi, V. (2011). Endocrine Therapy of Breast Cancer. Current Medicinal Chemistry. https://doi.org/10.2174/092986711794480177
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.